Building the Future of Biotech in Melbourne

2025 was the year Jumar’s connections expanded beyond our walls.

Looking back, we welcomed new residents and partners from across Victoria and interstate, while also beginning to build meaningful international bridges. From hosting visiting delegations and global leaders to forming partnerships with biotech companies around the world, Jumar has been actively connecting our startups with the expertise, capital, and opportunities that accelerate their growth.

Each collaboration, whether local or global, adds a new strand to our network of knowledge, resources, and talent that powers innovation and strengthens our mission to help science become real-world impact.

These relationships are more than symbolic.

They open pathways for our residents to collaborate, access international markets, and benchmark against the best in the world. At the same time, they bring fresh ideas and perspectives into our ecosystem - strengthening Australia’s role in the global innovation landscape.


What’s remarkable is how naturally this collaboration happens here. Conversations that begin in the lab or over coffee often evolve into projects and partnerships that span borders. It is a reminder that meaningful progress is rarely achieved alone, rather it's built through shared ambition and the willingness to learn from one another.

This progress was on full display at the recent Annual Jumar Showcase, where our residents presented the achievements and advances shaping their next stage of growth. We got to hear from:

• Arovella Therapeutics: Advancing CAR-iNKT cell therapies for cancer with strong preclinical data and a successful pre-IND meeting with the FDA.
• Inosi Therapeutics: Developing therapies to reverse fibrosis, supported by $968,000 in grant funding, matched by $2 million in investment.
• 23Strands: Pushing genomic medicine forward in fertility and women’s health.
• Misti: Transforming respiratory care with MedMisti® — the first super-sonic smart inhaler for home use.
• Proxima Bio: Building antibody-based degraders for safer autoimmune treatments, with promising human sample data.
• RAGE Bio: Creating novel therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE) for inflammatory diseases, and recently securing $29M in Series A funding to advance this work.
• PremieHealth: Developing next-generation nutrition to support organ development in premature infants.
• Denteric: Developing GPV381 for severe gum disease, having completed Phase I, secured CUREator+ Dementia funding to extend its platform into Alzheimer’s disease, and now preparing its IND submission.

As we look ahead to 2026, our focus is on deepening the partnerships and community that have defined this year. We will continue to expand our international connections, strengthen our support for founders, and build the programs that help early-stage teams grow with confidence.

Most importantly, we will keep fostering a place where collaboration happens naturally and scientific ambition is matched with practical support. 2025 has set a strong foundation, and we're ready to build on it.

If you'd like to receive the latest biotech news, events, and opportunities straight to your inbox - Subscribe to our newsletter.